跳至主要内容
临床试验/NCT02353260
NCT02353260Unknown2 期

A Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ultrasound Hyperthermia in Combination With Chemotherapy on Oral and Maxillofacial-Head and Neck Cancer

Wei Guo1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2014年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
发起方
入组人数
120
试验地点
1
主要终点
Rate of Disease Control

研究概览

简要总结

The purpose of this study is to determine whether Ultrasound Hyperthermia is effective and safe in the treatment of Oral and Maxillofacial-Head and Neck Cancer.

详细描述

As a non-invasive treatment, Ultrasound Hyperthermia has received increasing interest for the treatment of cancer.Many studies have shown that Therapeutic Ultrasound is safe and effective. Eligible patients were randomly assigned by using permutated blocks designed for each site to receive either Ultrasound Hyperthermia combined with chemotherapy (Arm A) or chemotherapy alone(Arm B).Chemotherapy will be conducted as follows. For Squamous cell carcinoma of head and neck,it will be administrated with Docetaxel(at a dose of 75 mg per square meter of body-surface area and intravenous infused in 1 hr at day 1rt), Cisplatin(at a dose of 75 mg per square meter of body-surface area and intravenous infused in 1 hr at day 1rt) and Fluorouracil(at a dose of 75 mg per square meter of body-surface area and intravenous infused last 5 days) . For other types of cancer,the treatments will be administrated in accord with the guideline.In addition,Ultrasound Hyperthermia will be conducted 5 times(day 1rt,3rd,5th,7th,9th) in Arm A. Patients in arm B will receive chemotherapy only. One cycle comprises a period of 3 weeks (21 days).All patients will receive 2 cycles in both arms. All the patients eligible for the operation will take surgery. After treatment,some patients with advanced unresectable cancer may be down-staged from stage IV, and will regain the opportunity of operation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Joined the study voluntary and signed informed consent form
  • Age 18-75,both genders.
  • Had histologically or cytologically confirmed advanced squamous cell carcinoma of the head and neck
  • At least one lesions can be measured,Conventional measurements ≥2cm, computed tomography(CT) examination ≥1cm .
  • Eastern Cooperative Oncology Group(ECOG) Performance Scale 0-
  • Life expectancy of more than 6 months.
  • Use of an effective contraceptive method for women when there is a risk of pregnancy during the study.
  • Haemoglobin≥90g/L ,White blood cell(WBC) ≥3×10^9/L
  • Hepatic function:ALAT、ASAT< 2.5 x ULN, TBIL< 1.5 x ULN
  • Renal function: Creatinine < 1.5 x ULN

排除标准

  • Participation in other interventional clinical trials within 1 month
  • Previous received other drug or operative treatment within 6 month
  • Pregnant or breast-feeding women
  • History of serious allergic or allergy
  • Patients with the history of Serious lung or head disease
  • Local skin ulceration

研究组 & 干预措施

Ultrasound Hyperthermia+Chemotherapy

Experimental

Chemotherapy:

  1. Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)
  2. The treatments will be administrated in accord with the guideline for other types of cancer.

Ultrasound Hyperthermia: Ultrasound hyperthermia d1,3,5,7,9/21d for 2 cycles

干预措施: Ultrasound Hyperthermia (Device)

Ultrasound Hyperthermia+Chemotherapy

Experimental

Chemotherapy:

  1. Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)
  2. The treatments will be administrated in accord with the guideline for other types of cancer.

Ultrasound Hyperthermia: Ultrasound hyperthermia d1,3,5,7,9/21d for 2 cycles

干预措施: Docetaxel,Cisplatin,Fluorouracil (Drug)

Chemotherapy

Active Comparator

Chemotherapy:

  1. Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2cycles)
  2. The treatments will be administrated in accord with the guideline for other types of cancer.

干预措施: Docetaxel,Cisplatin,Fluorouracil (Drug)

结局指标

主要结局

Rate of Disease Control

时间窗: one year

次要结局

  • Progression Free Survival(three years)
  • Over Survival(three years)

研究者

发起方
Wei Guo
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Wei Guo

Director in Dept.of Oral and Maxillofacial-Head and Neck Oncology

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

研究点 (1)

Loading locations...

相似试验